The TRANSCAN-3 network is pleased to announce the selection of 15 exceptional research consortia that will receive a combined total of €16.7 million in funding through the joint transnational call, “Combination Therapies Against Cancer: New Opportunities for Translational Research.”
This highly competitive funding initiative supports innovative, cross-disciplinary cancer research, bringing together top-tier scientists and clinicians from Europe, Türkiye and Canada. The selected projects will investigate novel therapeutic combinations, grounded in a deeper understanding of drug mechanisms and their influence on cancer development and progression.
Through this initiative, TRANSCAN-3 continues to champion research that aims to deliver more effective, personalized cancer treatments, with the ultimate goal of improving patient outcomes and quality of life.
TRANSCAN-3 is pleased to highlight the involvement of three international consortia that include Canadian researchers, supported through co-funding by our full partner, the Canadian Institutes of Health Research (CIHR), and our associated partner, the Cancer Research Society (CRS). This collaboration reflects a strong global commitment to advancing translational cancer research through international partnership.
The awarded projects are listed below in alphabetical order according to their acronym.
Project Acronym | Project Title |
| ACCELERATE | Functional precision medicine platform for the treatment of pancreatic cancer |
| BePrepared | Building an ex vivo complex tumour microenvironment platform for development of combination therapies and drug resistance studies in head neck cancer |
| DOPPLER-LC | Development Of Patient-derived organoid PLatform for Evading Resistances in Lung Cancer |
| GLIO-COMBO | Targeting tumor heterogeneity in pediatric high-grade gliomas |
| HAVOC | Human avatar on chip for advancing personalized cancer therapies by integrating vascular and immune components in a Tumor-on-Chip model |
| ioAVATAR | Immune oncology Drug Discovery & Decision - Advanced ex Vivo Approach To Accelerate Response prediction for combined therapies in ovarian cancer |
| LUNGOIDS | Subtype-specific Lung Cancer Organoids based on artificial ECM for Precision Oncology: Closing the Gap Between Preclinical Models and Patient Care |
| MELANOLOCK | Tackling resistance to immunotherapy in advanced melanomas through the inhibition of oncomiRs by Locked Nucleic Acids |
| METRICs* | Metabolism/Metagenomics-based strategies for sensitization to Radio- and Immuno- therapy Combinations |
| PREDICT-BC* | Patient-derived models for the Research and Evaluation of Discovery and Innovation in Combination Therapies for Biliary Cancer |
| SARAH* | Search for combinational therapy to target clonal haematopoiesis in solid malignancies |
| SeqPerGlio | Intraoperative tumour sequencing for personalized loco-regional drug combination therapy against glioblastoma recurrences |
| TITAN | Novel Cancer Therapy: Inducing Double-strand DNA Breaks to Foster Tumor Cell Death, Antigenicity and Immunotherapy Response in New Personalized Models |
| TOSCANINI | TAD disruption and aberrant expression as leukemia metabolic vulnerabilities for novel combination therapy tests in a drug screening platform |
| XPANTHER | Radiothermal-Driven Immune Activation to Tackle Pancreatic Hypoxic Tumors |
*Canadian researchers involved in these projects receive funding from the Canadian Institutes of Health Research (CIHR) and the Cancer Research Society (CRS)